Adjuvant chemotherapy for adults with malignant glioma: A systematic review

Canadian Journal of Neurological Sciences

Volumn 34, Issue 4, 2007, Pages 402-410

  Perry, James ^a,c   Laperriere, Normand ^b   Zuraw, Lisa ^c   Chambers, Alexandra ^c   Spithoff, Karen ^c   Cairncross, J Gregory ^d  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARMUSTINE; CISPLATIN; DIANHYDROGALACTITOL; FLUOROURACIL; LOMUSTINE; MITOLACTOL; NIMUSTINE; NITROSOUREA; PROCARBAZINE; STEROID; TEMOZOLOMIDE; TENIPOSIDE; VINCRISTINE;

ANEMIA; ARTICLE; AUTONOMIC NEUROPATHY; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COCHRANE LIBRARY; COGNITIVE DEFECT; COMPARATIVE STUDY; DECISION MAKING; EMBASE; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; HUMAN; LEUKOPENIA; MEDLINE; META ANALYSIS; MOOD DISORDER; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OLIGODENDROGLIOMA; ONCOLOGY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TUMOR BIOPSY;

EID: 37048999570     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100007265     Document Type: Article

References (37)

1. Mason W, Louis DN, Cairncross JG. Chemosensitive gliomas in adults: which ones and why? J Clin Oncol. 1997;15:3423-6.
2. Perry JR, DeAngelis LM, Schold SC Jr, Burger PC, Brem H, Brown MT, et al. Challenges in the design and conduct of phase III brain tumor therapy trials. Neurology. 1997;49:912-7.
3. Browman GP, Levine MN, Mohide EA, Hayward RS, Pritchard KI, Gafni A, et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol. 1995;13:502-12.
4. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359:1011-18.
5. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993;71:2585-97.
6. Edland RW, Javid M, Ansfield FJ. Glioblastoma multiforme. An analysis of the results of postoperative radiotherapy alone versus radiotherapy and concomitant 5-fluorouracil. (A prospective randomized study of 32 cases). Am J Roentgenol Radium Ther Nucl Med. 1971;111:337-42.
7. Brisman R, Housepian EM, Chang C, Duffy P, Balis E. Adjuvant nitrosourea therapy for glioblastoma. Arch Neurol. 1976;33: 745-50.
8. Reagan TJ, Bisel HF, Childs DS, Layton DD, Rhoton AL, Taylor WF. Controlled study of CCNU and radiation therapy in malignant astrocytoma. J Neurosurg. 1976;44:186-90.
9. Weir B, Band P, Urtasun R, Blain G, McLean D, Wilson F, et al. Radiotherapy and CCNU in the treatment of high-grade supratentorial astrocytomas [abstract]. J Neurosurg. 1976; 45:129-34.
10. Garrett MJ, Hughes HJ, Freedman LS. A comparison of radiotherapy alone with radiotherapy and CCNU in cerebral glioma. Clin Oncol. 1978;4:71-6.
11. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978;49:333-43.
12. E.O.R.T.C. Brain Tumor Group. Effect of CCNU on survival rate of objective remission and duration of free interval in patients with malignant brain glioma-final evaluation. Eur J Cancer. 1978;14:851-6.
13. Eagan RT, Childs DS Jr, Layton DD, Laws ER Jr, Bisel HF, Holbrook MA, et al. Dianhydrogalactitol and radiation therapy. Treatment of supratentorial glioma. JAMA. 1979;241:2046-50.
14. Solero CL, Monfardini S, Brambilla C, Vaghi A, Valagussa P, Mrello G, et al. Controlled study with BCNU vs. CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme. Cancer Clin Trials. 1979;2:43-8.
15. Cianfriglia F, Pompili A, Riccio A, Grassi A. CCNU-chemotherapy of hemispheric supratentorial glioblastoma multiforme. Cancer. 1980;45:1289-99.
16. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980;303:1323-9.
17. European Organization for Research on Treatment of Cancer (EORTC) Brain Tumor Group. Evaluation of CCNU, VM-26 plus CCNU, and procarbazine in supratentorial brain gliomas. Final evaluation of a randomized study. J Neurosurg. 1981;55:27-31.
18. Kristiansen K, Hagen S, Kollevold T, Torvik A, Holme I, Nesbakken R, et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer. 1981;47: 649-52.
19. Chin HW, Young AB, Maruyama Y. Survival response of malignant gliomas to radiotherapy with or without BCNU or methyl-CCNU chemotherapy at the University of Kentucky Medical Center. Cancer Treat Rep. 1981;65:45-51.
20. Green SB, Byar DP, Walker MD, Pistenmaa DA, Alexander E Jr, Batzdorf U, et al. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep. 1983;67:121-32.
21. Afra D, Kocsis B, Dobay J, Eckhardt S. Combined radiotherapy and chemotherapy with dibromodulcitol and CCNU in the postoperative treatment of malignant gliomas. J Neurosurg. 1983;59:106-10.
22. Ushio Y, Hayakawa T, Hasegawa H, Yamada K, Arita N. Chemotherapy of malignant gliomas. Neurosurg Rev. 1984;7: 3-12.
23. Hatlevoll R, Lindegaard KF, Hagen S, Kristiansen K, Nesbakken R, Torvik A, et al. Combined modality treatment of operated astrocytomas grade 3 and 4. A prospective and randomized study of misonidazole and radiotherapy with two different radiation schedules and subsequent CCNU chemotherapy. Stage II of a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer. 1985;56:41-7.
24. Takakura K, Abe H, Tanaka R, Kitamura K, Miwa T, Takeuchi K, et al. Effects of ACNU and radiotherapy on malignant glioma. J Neurosurg. 1986;64:53-7.
25. Nelson DF, Diener-West M, Horton J, Chang CH, Schoenfeld D, Nelson JS. Combined modality approach to treatment of malignant gliomas-re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr. 1988;279-84.
26. Trojanowski T, Peszynski J, Turowski K, Kaminski S, Goscinski I, Reinfus M, et al. Postoperative radiotherapy and radiotherapy combined with CCNU chemotherapy for treatment of brain gliomas. J Neurooncol. 1988;6:285-91.
27. EORTC Brain Tumor Group. Cisplatin does not enhance the effect of radiation therapy in malignant gliomas. Eur J Cancer. 1991;27:568-71.
28. EORTC Brain Tumor Group. Hildebrand J, Sahmoud T, Mignolet F, Brucher JM, Afra D. Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. Neurology. 1994;44:1479-83.
29. Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol. 2001;19:509-18.
30. Stupp R, Mason WP, van den Bent MJ, Weiler M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352:987-96.
31. Athanassiou H, Synodinou M, Maragoudakis E, Paraskevaidis M, Verigos C, Misailidou D, et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol. 2005;23:2372-7.
32. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJB, Bernsen HJJA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24:2715-22.
33. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006; 24:2707-14.
34. Taphoorn MJB, Stupp R, Coens C, Osoba D, Kortmann, R, van den Bent MJ, et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol. 2005;6:937-44.
35. Curran WJ, Jr., Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Nat Cancer Inst. 1993;85:704-10.
36. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90:1473-9.
37. Hegi ME, Diserens A, Gorlia T, Hamou M, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.